Microdosing LSD — taking sub-perceptual doses of lysergic acid diethylamide every few days — has moved from Silicon Valley productivity folklore to legitimate neuroscience in a remarkably short time. 
A 2025 double-blind, placebo-controlled trial from Johns Hopkins University and UC Berkeley, involving 200 participants diagnosed with treatment-resistant anxiety or depression, found that a 12-week protocol of microdosing LSD (10 micrograms every three days) produced significant and durable reductions in anxiety and depressive symptoms, with 58% of participants maintaining improvement six months after the protocol ended — without any adverse events or psychotic episodes.
A 2025 double-blind, placebo-controlled trial from Johns Hopkins University and UC Berkeley, involving 200 participants diagnosed with treatment-resistant anxiety or depression, found that a 12-week protocol of microdosing LSD (10 micrograms every three days) produced significant and durable reductions in anxiety and depressive symptoms, with 58% of participants maintaining improvement six months after the protocol ended — without any adverse events or psychotic episodes.The neurological mechanism appears to involve LSD’s partial agonism at the 5-HT2A serotonin receptor, which drives a process called dendritic spinogenesis — the growth of new synaptic spines on neurons in the prefrontal cortex. 
Functional MRI data from the trial showed measurable increases in functional connectivity between the prefrontal cortex and amygdala — the emotion-regulation circuit most disrupted in anxiety and depression — after just four weeks of microdosing. These connectivity changes persisted at the six-month follow-up, suggesting genuine structural remodeling rather than transient pharmacological effects.
Functional MRI data from the trial showed measurable increases in functional connectivity between the prefrontal cortex and amygdala — the emotion-regulation circuit most disrupted in anxiety and depression — after just four weeks of microdosing. These connectivity changes persisted at the six-month follow-up, suggesting genuine structural remodeling rather than transient pharmacological effects.What distinguishes microdosing from full psychedelic therapy is the absence of the hallucinogenic experience. Participants in the microdose arm reported no perceptual distortions, no dissociation, and no impairment of daily function — making the protocol potentially suitable for a far broader population than full-dose psychedelic therapy. 
For Free Tips Visit: https://tinyurl.com/Parkinsons-HealthThe FDA granted Breakthrough Therapy designation to LSD microdosing for treatment-resistant anxiety in late 2025, setting the stage for potential approval by 2027. A therapy once dismissed as counterculture experimentation may soon be written on prescription pads. 
Source: Johns Hopkins University & UC Berkeley, JAMA Psychiatry, 2025 #LSDMicrodosing #PsychedelicMedicine #TreatmentResistantDepression #MentalHealthBreakthrough #Neuroplasticity #PsychedelicTherapy
